Scancell (LON:SCLP) Stock Price Down 3.2% - Should You Sell?

Key Points

• Scancell Holdings plc shares dropped by 3.2% during mid-day trading, with the stock closing at GBX 9.69 ($0.13) after trading as low as GBX 9.60.
• The company reported a market capitalization of £99.83 million and has a significant debt-to-equity ratio of -566.79.
• Insider Martin Diggle purchased 4.4 million shares at an average price of GBX 10 per share, representing a total investment of £440,000.

Scancell Holdings plc (LON:SCLP - Get Free Report) dropped 3.2% during trading on Wednesday . The stock traded as low as GBX 9.60 ($0.13) and last traded at GBX 9.69 ($0.13). Approximately 1,336,894 shares changed hands during mid-day trading, an increase of 44% from the average daily volume of 925,977 shares. The stock had previously closed at GBX 10 ($0.13).

Scancell Price Performance

The company's fifty day moving average is GBX 10.15 and its 200 day moving average is GBX 9.63. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The stock has a market cap of £91.12 million, a PE ratio of -422.12 and a beta of 0.35.

Insider Buying and Selling

In other Scancell news, insider Martin Diggle purchased 4,400,000 shares of the business's stock in a transaction that occurred on Friday, August 1st. The shares were purchased at an average price of GBX 10 per share, for a total transaction of £440,000. Insiders own 15.15% of the company's stock.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.